Last reviewed · How we verify
Empiric Therapy: Drug
Empiric Therapy: Drug () is a marketed product developed by Vanderbilt University Medical Center, with a key composition patent expiring in 2028. The drug's market position and specific mechanism of action are not detailed, but its patent protection provides a competitive advantage until expiry. The primary risk is the potential loss of exclusivity and increased competition post-2028.
At a glance
| Generic name | Empiric Therapy: Drug |
|---|---|
| Sponsor | Vanderbilt University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Immediate Versus Substantiated Antibiotic Therapy in Suspected Non-Severe Ventilator-Associated Pneumonia (NA)
- Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia (PHASE4)
- Feasibility of Process-based Therapy in a Naturalistic Setting (NA)
- Efficacy of an Empirical Treatment With Amoxicillin-clavulanate (AC) Compared to the Combination Amoxicillin-clavulanate and Ciprofloxacin (AC+C) in the Outpatient Care of Chemotherapy-induced Fever in Adult Haematology Patients. (PHASE3)
- Aminoglycosides in Early Sepsis (PHASE4)
- Enhancing Smoking Cessation for African American People Everywhere (PHASE2)
- Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant (PHASE2)
- Study on the Safety and Tolerability of Postoperative Radiotherapy Concurrent With CDK4/6 Inhibitors in HR+/HER2- High-Risk Breast Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Empiric Therapy: Drug CI brief — competitive landscape report
- Empiric Therapy: Drug updates RSS · CI watch RSS
- Vanderbilt University Medical Center portfolio CI